Why Lipase

The inability to fully access the caloric density of fats is a challenge for patients relying on enteral nutrition who may lack the inability to properly and effectively hydrolyze available fats.

  • Of the digestive enzymes, lipases have the ability to hydrolyze, or digest, fats (amylase acts on starches and protease acts on proteins)
  • Further, proteins and starches are digested in multiple parts of the gastrointestinal tract, whereas fats remain mostly unchanged until they reach the small intestine and interact with pancreatic lipase
  • Pancreatic lipase accounts for up to 90% of fat digestion

Not all lipases are created equal; certain lipases have the ability to hydrolyze long-chain triglycerides (LCTs), which are difficult to digest.

Like human pancreatic lipase, the lipase in RELiZORB is intended to selectively cleave triglycerides at the sn-1 and sn-3 positions, but without the need for co-lipase. The lipase in RELiZORB has optimal activity at the pH of enteral formulas.

RELiZORB is designed to mimic the function of pancreatic lipase and hydrolyze available fats prior to ingestion of enteral formula.

Check out the data on RELiZORB.

Lipase, iLipase™, and RELiZORB In Action

Fats varying in fatty acid chain lengths are hydrolyzed and absorbed differently. Both medium-chain triglycerides (MCTs) and LCTs provide calories, but LCTs are especially important in nutritionally challenged patients.

Lipase is the digestive enzyme that makes calories from LCTs and MCTs available to the body. Inside the RELiZORB cartridge is lipase that is bound and immobilized to small white beads (iLipase).

With RELiZORB, fats are hydrolyzed in their triglyceride form, including important LCTs.

Fatty acids, such as omega-3 fats, DHA (docosahexaenoic acid), and EPA (eicosapentaenoic acid), are released into their fatty acid and monoglyceride forms and become available to be absorbed by the patient.